primary central nervous system lymphoma
Conditions
Interventions
Experimental group:Pomalidomide and Zanubrutinib
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Initial diagnosis of primary central nervous system lymphoma; 2.The pathological type was B-cell lymphoma; 3.Age 18-80 years old; 4.Human Immunodeficiency Virus (HIV) negative; 5.Initial treatment patients who have not received radiotherapy, chemotherapy, or targeted therapy; 6.No bone marrow hematopoietic dysfunction, the following indicators should be met: white blood cell count >3.0×10^9/L, neutrophil absolute pair value >1.5×10^9/L, hemoglobin concentration >90g/L, platelet count >80×10^9/L; 7.No major organ dysfunction, must meet the following criteria: Cardiac function grade 0-2 (NYHA); Blood oxygen saturation > 88% (natural state); Alanine aminotransferase 60ml/min; 8.At least one measurable lesion; 9.Patients voluntarily sign informed consent forms;
Exclusion criteria
Exclusion criteria: 1.The pathological diagnosis was T cell lymphoma; 2.Systemic lymphoma involves the central nervous system; 3.Patients with uncontrolled medical disease (including severe organ dysfunction, uncontrolled active infection, interstitial pneumonia, etc.); 4.For patients with mental disorders; 5.Acute myocardial infarction or unstable angina or hypertension and arrhythmia within 6 months; 6.active hemorrhage; 7.Allergic to the drug being tested; 8.Patients who can not be treated according to the plan, poor compliance, or the doctor thinks that the group should be removed; 9.A woman who is pregnant or breastfeeding;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival;Overall survival;adverse reaction; | — |
Countries
China
Contacts
Public ContactWu Di
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed